FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Triamterene and Hydrochlorothiazide (Dyazide) Capsules
Status: Discontinuation
»Therapeutic Categories: Cardiovascular

GlaxoSmithKline (New 11/16/2020)

Company Contact Information:

Presentation Posting Date Related Information
25 mg; 37.5 mg (NDC 0007-3650-22) 11/16/2020 This product discontinuation is a business related decision. The anticipated date that GSK will cease distribution of the product is approximately December 2020.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English